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Dosimetric verifi cation of the dose 
calculation algorithms in real time prostate 
brachytherapy
Marta MOCNA, Grzegorz ZWIERZCHOWSKI
SUMMARY
BACKGROUND: During real time prostate brachytherapy different calculation algorithms can be used 
which gives the opportunity to modulate the dwell times and positions of the source and consequent-
ly the dose distribution and values of therapeutic indices [1].
AIM: The aim of this study was the dosimetric verifi cation (in-phantom) of three optimization algo-
rithms for dose calculation during real-time prostate brachytherapy. 
MATERIALS/METHODS: Three optimization algorithm were evaluated: geometric optimization (GO), 
inverse optimization (IO) and blind inverse optimization (BIO). Then treatment plans for the tissue-
equivalent phantom were prepared. For each plan the same CTV, organs at risk (OARs: urethra, rec-
tum), number of needles and geometry of implant were used.
RESULTS: Measured mean doses and their standard deviations for GO, IO and BIO were respectively: 
11.13 Gy and 0.01 Gy, 15.71 Gy and 0.01 Gy, 14.74 Gy and 0.02 Gy for the urethra and 10.11 Gy and 
0.01 Gy, 8.97 Gy and 0.01 Gy, 8.70 Gy and 0.01 Gy for the rectum. Comparison between doses mea-
sured by semiconductor detectors and calculated doses revealed differences in the range from 0.10 Gy 
between doses compared in the urethra for IO and BIO even to 2.46 Gy for GO for the same analyzed 
organ. For the rectum these differences were between 0.32 and 0.66 Gy.
CONCLUSIONS: Qualitative comparative analysis performed for a phantom study for 3D-CBRT pros-
tate treatment proved the correctness of verifi  ed optimization algorithms implemented in Oncentra 
Prostate vs. 3.0.9.
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External beam radiotherapy followed by a tem-
porary high dose rate afterloading implant is a 
clinically used procedure for the treatment of 
prostate cancer. The second part of this com-
bined schedule consists of 3D conformal real 
time HDR brachytherapy (3D-CBRT) with an 
Iridium 192 source and it is used mostly as a 
boost [3, 4, 5, 6]. The single radioactive step-
ping source moves through all the implanted 
needles according to the prepared in real-time 
treatment plan. Delivering higher radiation 
doses precisely to the prostate and achieving 
optimal dose conformity is possible with the 
ability to optimize dwell times and positions 
along the implanted needles [7]. The use of 
different calculation algorithms gives the op-
portunity to modulate these dwell times and 
positions of the source which result in dose 
distribution modulation and consequently the 
values of therapeutic indices. 
In the Brachytherapy Department of the 
Greater Poland Cancer Centre, 3D-CBRT is 
applied in a single treatment session or in 2 
fractions giving 15 or 10 Gy per fraction [6, 8]. 
Planning and execution of real-time prostate 
brachytherapy is carried out in HDR bunker 
[9]. The whole treatment procedure is ultra-
sonography guided irradiation of CTV – pros-
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tate gland while sparing the dose to organs at 
risk (urethra, bladder) [10, 11, 12]. The whole 
geometry is reconstructed based on transverse 
images from transrectal ultrasound (TRUS). 
Next the pre-planning procedure is carried 
out. Treatment plan based on reconstructed 
geometry (Virtual Plan, VP) is prepared. The 
number of needles and their positions are de-
fi ned to achieve the clinically acceptable dose 
distribution for the treated patient [13, 14]. 
After needle insertion under ultrasound guid-
ance, new image set acquisition is performed. 
Anatomical structures are redefi ned and the 
positions of needles are verifi ed [15]. Then op-
timization is performed for the new geometry 
of implant and volumes of interest which are 
reconstructed in real time. Dose distribution 
is calculated even several times to generate 
the plan which can be accepted from a clinical 
point of view. This fi nal plan is called Live Plan 
(LV) and it is used for treatment delivery [9].
AIM
The aim of this study was the dosimetric 
verifi cation (in-phantom) of three different 
optimization algorithms used in the dose cal-
culation process during real-time prostate 
brachytherapy by comparing the doses cal-
culated in Oncentra Prostate® vs. 3.0.9 treat-
ment planning system with doses measured 
by using semiconductor detectors.
MATERIALS AND METHODS
Doses in urethra and rectum were measured 
with semiconductor detectors: single semicon-
ductor detector bladder probe (T9113 PTW 
Freiburg®) and fl exible fi ve semiconductor de-
tectors rectum probe (T9112 PTW Freiburg®). 
These detectors are dedicated to in-vivo do-
simetry. The fl exible bladder probe has one de-
tector with 3 mm diameter which is located 8 
mm from the tip of the probe. The second used 
probe (rectum) consists of fi ve single detectors. 
They are spaced 15 mm apart from each other, 
which increases the probability to measure 
the maximum of the rectum dose. Both probes 
were connected to the detector connection 
box, which was linked to a Multi Channel Do-
simeter MULTIDOS PTW Freiburg®. Probes 
were placed in an anatomical tissue-equivalent 
phantom – semiconductor bladder probe in the 
urethra and semiconductor rectum probe in 
the rectum. Apart from placement of probes, 
the whole treatment and planning procedure 
was done as usual. The phantom used in the 
study with probes and implanted needles is 
shown in Figure 1.
Fig. 1. The tissue-equivalent phantom with needles 
placed, bladder and rectum probes, used for dosimetric 
verifi cation of the dose distribution in real time prostate 
brachytherapy
After acquisition of images treatment plans 
for tissue-equivalent phantom were prepared 
using Oncentra Prostate® vs. 3.0.9 treatment 
planning system. For each optimization al-
gorithm (GO, IO, BIO) three plans were pre-
pared. In each plan the volume of CTV, the 
volume of OARs, number of needles and geom-
etry of implant were exactly the same. Pros-
tate (CTV), urethra, rectum and used probes 
were outlined on ultrasound images. Unfor-
tunately there was no technical possibility to 
determine reference points in places where 
the detectors were placed. That is why the 
authors decided to compare maximum doses 
calculated in used TPS with measured doses 
and to analyze the tendencies in dose distribu-
tion which is assumed to be acceptable from a 
clinical point of view [16–19]. 
RESULTS
Three series of measurements for each used 
optimization algorithm were made. The pre-
scribed dose was 10 Gy in every case. Re-
sults of doses measured using semiconductor 
probes with mean values and standard devia-
tion (SD) are shown in Table 1.
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Maximum doses calculated by TPS are 
shown in Table 2. 
As mentioned above, the trends in dose dis-
tribution in OARs achieved by using different 
optimization algorithms were analyzed. These 
trends are shown in Figure 2 (for urethra) and 
Figure 3 (for rectum).
DISCUSSION
The quality of HDR prostate brachytherapy 
implantations is evaluated by controlling the 
dose volume histogram parameters for CTV 
and OARs. Delivering high homogenous doses 
precisely to the prostate gland while sparing 
the dose in urethra and rectum need to be 
controlled in every clinical case [15]. Geomet-
ric dependencies between CTV and critical 
organs are not common in other clinical cases 
(OARs inside or in very close proximity to the 
CTV). That is why in this study the phantom 
Series of measurements GO IO BIO
DU [Gy] DR [Gy] DU [Gy] DR [Gy] DU [Gy] DR [Gy]
1 11,14 10,11 15,81 8,96 14,76 8,72
2 11,12 10,09 15,82 8,98 14,74 8,70
3 11,14 10,12 15,80 8,96 14,72 8,69
Dm 11,13 10,11 15,81 8,97 14,74 8,70
SD 0,01 0,01 0,01 0,01 0,02 0,01
Table 1. Doses measured using different optimization algorithms (GO, IO, BIO) by semiconductor probes implemented in 
used tissue-equivalent phantom: DU in urethra, DR in rectum with mean values (DM) and standard deviation (SD)
Optimizationalgorithm Urethra Rectum
D10 [Gy] Dmax [Gy] D10 [Gy] Dmax [Gy]
GO 11,41 13,59 9,11 10,77
IO 13,49 15,91 7,97 9,29
BIO 12,81 14,84 7,92 9,13
Table 2. Doses calculated in Oncentra Prostate® vs. 3.0.9 treatment planning system using different optimization algo-
rithms
Fig. 2. The tendencies in dose distribution in urethra 
achieved by using different optimization algorithms 
(GO-Geometrical Optimization, IO-Inverse Optimization, 
BIO-Blind Inverse Optimization)
Fig. 3. The tendencies in dose distribution in rectum 
achieved by using different optimization algorithms 
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was used by the authors to perform the mea-
surements using semiconductor probes.
Three series of measurements for each eval-
uated optimization algorithm were performed. 
For each received dose in each analyzed OAR 
and optimization algorithm respectively, the 
average values with standard deviations (SD) 
were calculated. This verifi cation confi rmed 
that the optimization algorithms implement-
ed in Oncentra Prostate® vs. 3.0.9 treatment 
planning system seem to be working correctly. 
Although there were some technical diffi cul-
ties with defi ning the reference points in plac-
es where the semiconductor detectors were 
placed, the whole study gives the opportunity 
to verify the values of maximal doses calculat-
ed by used TPS. Results showed that for some 
of the measurements the differences occurred 
between measured and calculated doses, but 
the fi nal conclusion was based on the qualita-
tive tendencies in achieving dose distribution 
acceptable from a clinical point of view in 
chosen OARs. Analyzing these tendencies, the 
highest maximum doses in the rectum were 
measured and calculated using GO, the lowest 
maximum doses were measured and calculat-
ed using BIO. Results achieved for the urethra 
were the same, meaning the tendencies also 
show that the highest maximum doses were 
measured and calculated for the same optimi-
zation algorithm but this time it was IO. The 
lowest measured and calculated doses in the 
urethra were achieved using GO.  
Technical problems with precise localiza-
tion of the active area of semiconductor probes 
are also very important while in-vivo dosim-
etry is going to be performed. Controlled mea-
surements of the doses deposited in irradiated 
volumes are rather diffi cult to achieve. Detec-
tors are located in a high dose gradient area 
and inaccurate positioning (even single mil-
limetres of shift) of semiconductor detectors 
could have a strong infl uence on the measured 
doses. 
Needle implantation could be ‘non-opti-
mal’. From a clinical point of view, anatomy 
of the patient could be the limiting factor in 
achieving eligible dose distribution. In such 
conditions even small differences in dose dis-
tribution for critical organs could be the de-
terminant factors for treating or not treating 
the patient using a particular treatment plan. 
When the whole procedure is time limited 
(patient in anaesthesia) fast and reliable tools 
for achieving clinically acceptable treatment 
plans are essential during daily practice.
In operation theatre conditions, in-vivo do-
simetry during real time procedure is in most 
cases diffi cult to perform. The use of a phan-
tom ensures repeatable geometric relations 
between the needles (implant) and treated 
volume and corresponding organs at risk and 
also makes dose distribution verifi cation pos-
sible. Knowing the limitations of optimiza-
tion algorithms is essential to make proper 
clinical decisions during real-time planned 
brachytherapy of the prostate. 
CONCLUSIONS
1. The tissue-equivalent phantom used by 
the authors was useful for measurements us-
ing semiconductor rectum and bladder probes 
in real time prostate HDR brachytherapy.
2. On the basis of qualitative analysis of the 
calculated and measured doses, the correct-
ness of dose distribution achieved by using 
different optimization algorithms implement-
ed in Oncentra Prostate vs. 3.0.9 treatment 
planning system was proved. 
3. The calculations demonstrate that when 
the same geometry of the whole implant is 
used (volume of CTV, OARs’ volume, number 
of needles) the fi nal dose distribution depends 
only on the used optimization algorithm. 
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